Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT.

Journal article

Although the feasibility of using HLA-mismatched unrelated donors as an alternate graft source for haematopoietic SCT (HSCT) has been shown, little is known about the safety of HLA-mismatched DLI for the treatment of relapse. We examined the outcome of 58 consecutive leukaemia patients who received escalating-dose DLI for treatment of relapse after alemtuzumab-conditioned myeloablative unrelated donor HSCT at our institution. High-resolution HLA typing on stored DNA samples revealed mismatche...

Expand abstract

Authors: Innes, A; Beattie, R; Sergeant, R; Damaj, D; Foroni, L

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Nature Publishing Group
• Journal: Bone Marrow Transplantation
• Volume: 48
• Issue: 10
• Pages: 1324-1328
• Publication date: 2013-10-01
• Acceptance date: 2013-03-30
• DOI: 10.1038/bmt.2013.69
• EISSN: 1476-5365
• ISSN: 0268-3369
• Language: English
• Keywords: Treatment Outcome; Female; Humans; Adolescent; T-Lymphocytes; Retrospective Studies; Neoplasm Recurrence, Local; Transplantation, Homologous; Middle Aged; Adult; Antibodies, Monoclonal, Humanized; Histocompatibility; HLA Antigens; Young Adult; Stem Cell Transplantation; Leukemia; Male